Anavex comments on failure of Pfizer and Medivation's Alzheimer's Investigational drug Dimebon
- Details
- Category: Clinical Trials
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) issued a statement following the announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment
- Details
- Category: Novo Nordisk
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Norditropin® FlexPro®, a new prefilled growth hormone injection pen to be used by children and adults.
FDA Advisory Committee Recommends Approval of Belatacept
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients.
Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals
- Details
- Category: Abbott
Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott.
Nycomed on track in 2009 with strong growth in Key Products
- Details
- Category: Nycomed
Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantoprazole sales were resilient after the loss of exclusivity in May in 12 European countries, as a result of a tailored approach to each region.
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report") by releasing a White Paper.
More Pharma News ...
- Phase III study of Avastin in advanced stomach cancer did not meet primary endpoint
- Pfizer's Prevnar 13 Recommended by CDC's Advisory Committee On Immunization Practices
- FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
- Lilly, Merck, And Pfizer Announce the Formation of the Asian Cancer Research Group, Inc.
- Novartis receives FDA approval of Menveo®
- US FDA approves Rituxan/MabThera for the most common type of adult leukemia
- GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia